 Deborah Hall
Concepts (315)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Fragile X Syndrome | 26 | 2021 | 178 | 8.760 |
Why?
| | Tremor | 24 | 2021 | 136 | 8.120 |
Why?
| | Fragile X Mental Retardation Protein | 27 | 2021 | 107 | 7.600 |
Why?
| | Ataxia | 24 | 2021 | 79 | 7.320 |
Why?
| | Parkinson Disease | 23 | 2022 | 1180 | 4.430 |
Why?
| | Parkinsonian Disorders | 10 | 2021 | 210 | 3.360 |
Why?
| | Heterozygote | 11 | 2022 | 115 | 3.210 |
Why?
| | Trinucleotide Repeat Expansion | 11 | 2021 | 43 | 2.740 |
Why?
| | Tinnitus | 4 | 2020 | 11 | 1.880 |
Why?
| | Humans | 83 | 2022 | 31481 | 1.600 |
Why?
| | Cognition Disorders | 6 | 2021 | 1075 | 1.480 |
Why?
| | Supranuclear Palsy, Progressive | 8 | 2020 | 45 | 1.420 |
Why?
| | Gait Disorders, Neurologic | 3 | 2020 | 150 | 1.360 |
Why?
| | Postural Balance | 5 | 2020 | 127 | 1.350 |
Why?
| | Research Design | 5 | 2020 | 238 | 1.320 |
Why?
| | Neurology | 2 | 2018 | 113 | 1.300 |
Why?
| | Female | 50 | 2022 | 18253 | 1.220 |
Why?
| | Cerebellar Ataxia | 2 | 2021 | 7 | 1.220 |
Why?
| | Trinucleotide Repeats | 2 | 2018 | 10 | 1.180 |
Why?
| | Aged | 40 | 2022 | 10295 | 1.160 |
Why?
| | Male | 49 | 2022 | 17583 | 1.150 |
Why?
| | Executive Function | 2 | 2018 | 109 | 1.120 |
Why?
| | Middle Aged | 41 | 2022 | 11209 | 1.110 |
Why?
| | Accidental Falls | 4 | 2020 | 118 | 1.030 |
Why?
| | African Americans | 2 | 2021 | 818 | 1.010 |
Why?
| | Phenotype | 9 | 2022 | 379 | 0.980 |
Why?
| | Biomedical Research | 2 | 2018 | 89 | 0.970 |
Why?
| | Exercise Therapy | 3 | 2018 | 116 | 0.950 |
Why?
| | Advance Care Planning | 1 | 2022 | 13 | 0.930 |
Why?
| | Huntington Disease | 1 | 2022 | 61 | 0.890 |
Why?
| | Spinocerebellar Degenerations | 1 | 2021 | 4 | 0.890 |
Why?
| | Cytidine Diphosphate Choline | 1 | 2020 | 4 | 0.830 |
Why?
| | Psychomotor Performance | 2 | 2020 | 258 | 0.820 |
Why?
| | Nootropic Agents | 1 | 2020 | 14 | 0.820 |
Why?
| | Patient Selection | 2 | 2018 | 264 | 0.800 |
Why?
| | Auditory Perception | 2 | 2017 | 49 | 0.780 |
Why?
| | Walking | 4 | 2020 | 249 | 0.770 |
Why?
| | Attention | 1 | 2020 | 163 | 0.760 |
Why?
| | Delphi Technique | 2 | 2020 | 26 | 0.740 |
Why?
| | Hearing | 2 | 2021 | 18 | 0.740 |
Why?
| | Movement Disorders | 2 | 2016 | 150 | 0.710 |
Why?
| | Acoustics | 1 | 2017 | 17 | 0.700 |
Why?
| | Clinical Trials as Topic | 2 | 2018 | 378 | 0.690 |
Why?
| | Cognition | 4 | 2022 | 1206 | 0.690 |
Why?
| | Case-Control Studies | 10 | 2021 | 687 | 0.680 |
Why?
| | Psychotherapy | 1 | 2017 | 44 | 0.670 |
Why?
| | Polymerase Chain Reaction | 2 | 2016 | 188 | 0.650 |
Why?
| | Memory Disorders | 2 | 2016 | 181 | 0.640 |
Why?
| | Mutation | 4 | 2022 | 464 | 0.600 |
Why?
| | Cerebral Hemorrhage | 4 | 2021 | 141 | 0.580 |
Why?
| | DNA Methylation | 1 | 2016 | 168 | 0.570 |
Why?
| | Severity of Illness Index | 11 | 2020 | 1240 | 0.560 |
Why?
| | Aged, 80 and over | 16 | 2021 | 5234 | 0.560 |
Why?
| | Genetic Predisposition to Disease | 3 | 2021 | 462 | 0.540 |
Why?
| | Adult | 18 | 2021 | 9779 | 0.520 |
Why?
| | Treatment Outcome | 10 | 2020 | 3910 | 0.510 |
Why?
| | Acoustic Stimulation | 1 | 2013 | 65 | 0.510 |
Why?
| | Neuropsychological Tests | 8 | 2022 | 1300 | 0.500 |
Why?
| | Genetic Testing | 4 | 2021 | 73 | 0.480 |
Why?
| | Alleles | 3 | 2020 | 221 | 0.460 |
Why?
| | Communication Disorders | 1 | 2011 | 5 | 0.450 |
Why?
| | Activities of Daily Living | 4 | 2017 | 495 | 0.430 |
Why?
| | Dyskinesia, Drug-Induced | 2 | 2021 | 52 | 0.430 |
Why?
| | Deafness | 2 | 2021 | 12 | 0.430 |
Why?
| | Chromosomes, Human, X | 2 | 2009 | 8 | 0.430 |
Why?
| | Cochlear Implantation | 2 | 2021 | 18 | 0.420 |
Why?
| | Quality of Life | 4 | 2022 | 663 | 0.420 |
Why?
| | Retrospective Studies | 8 | 2022 | 3591 | 0.420 |
Why?
| | Gait | 4 | 2020 | 395 | 0.410 |
Why?
| | Sex Chromosome Aberrations | 1 | 2009 | 1 | 0.410 |
Why?
| | Chromosomes, Human, Y | 1 | 2009 | 1 | 0.410 |
Why?
| | Shoulder Pain | 1 | 2010 | 57 | 0.400 |
Why?
| | Speech Perception | 2 | 2021 | 56 | 0.400 |
Why?
| | Dopamine | 1 | 2010 | 162 | 0.390 |
Why?
| | Quinolones | 1 | 2009 | 23 | 0.380 |
Why?
| | Pilot Projects | 3 | 2020 | 455 | 0.370 |
Why?
| | Antipsychotic Agents | 1 | 2009 | 89 | 0.360 |
Why?
| | Consensus | 2 | 2020 | 106 | 0.360 |
Why?
| | Motor Activity | 3 | 2021 | 397 | 0.350 |
Why?
| | Piperazines | 1 | 2009 | 99 | 0.350 |
Why?
| | Risk Factors | 8 | 2021 | 2664 | 0.350 |
Why?
| | Students, Health Occupations | 1 | 2007 | 5 | 0.340 |
Why?
| | Science | 1 | 2007 | 6 | 0.340 |
Why?
| | Celiac Disease | 1 | 2007 | 10 | 0.340 |
Why?
| | Dystonia | 1 | 2007 | 55 | 0.330 |
Why?
| | Central Nervous System Agents | 1 | 2006 | 8 | 0.330 |
Why?
| | Clinical Laboratory Techniques | 1 | 2007 | 38 | 0.330 |
Why?
| | Pregnancy in Diabetics | 1 | 2006 | 4 | 0.330 |
Why?
| | Fetal Distress | 1 | 2006 | 2 | 0.330 |
Why?
| | Teaching | 1 | 2007 | 68 | 0.320 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2006 | 16 | 0.320 |
Why?
| | Infant, Newborn, Diseases | 1 | 2006 | 18 | 0.320 |
Why?
| | Seizures | 1 | 2006 | 88 | 0.300 |
Why?
| | Cross-Sectional Studies | 5 | 2020 | 986 | 0.300 |
Why?
| | Disability Evaluation | 5 | 2016 | 332 | 0.280 |
Why?
| | Hyperglycinemia, Nonketotic | 1 | 2004 | 1 | 0.280 |
Why?
| | Neurotoxicity Syndromes | 1 | 2004 | 4 | 0.280 |
Why?
| | Chorea | 1 | 2004 | 13 | 0.280 |
Why?
| | Eye Movements | 2 | 2021 | 26 | 0.270 |
Why?
| | United States | 3 | 2020 | 2539 | 0.270 |
Why?
| | Exercise | 3 | 2017 | 454 | 0.270 |
Why?
| | RNA, Messenger | 3 | 2018 | 371 | 0.260 |
Why?
| | Time Factors | 5 | 2020 | 1902 | 0.260 |
Why?
| | Diffusion Magnetic Resonance Imaging | 2 | 2021 | 115 | 0.250 |
Why?
| | Alzheimer Disease | 1 | 2014 | 1829 | 0.250 |
Why?
| | Cohort Studies | 4 | 2016 | 2014 | 0.250 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2022 | 12 | 0.240 |
Why?
| | Neurosecretory Systems | 1 | 2022 | 14 | 0.240 |
Why?
| | Incidence | 3 | 2020 | 829 | 0.240 |
Why?
| | Weather | 2 | 2019 | 18 | 0.240 |
Why?
| | Advance Directives | 1 | 2022 | 5 | 0.240 |
Why?
| | Glucosylceramidase | 1 | 2022 | 22 | 0.230 |
Why?
| | Documentation | 1 | 2022 | 27 | 0.230 |
Why?
| | Brain | 4 | 2022 | 1655 | 0.230 |
Why?
| | Multiple System Atrophy | 1 | 2022 | 42 | 0.230 |
Why?
| | Biomechanical Phenomena | 4 | 2020 | 719 | 0.230 |
Why?
| | Longitudinal Studies | 3 | 2021 | 1452 | 0.230 |
Why?
| | Food | 1 | 2021 | 32 | 0.230 |
Why?
| | Dopamine Agents | 1 | 2021 | 42 | 0.230 |
Why?
| | Subthalamic Nucleus | 1 | 2022 | 36 | 0.230 |
Why?
| | Primary Ovarian Insufficiency | 1 | 2021 | 7 | 0.230 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2021 | 17 | 0.220 |
Why?
| | Ovary | 1 | 2021 | 35 | 0.220 |
Why?
| | Cerebral Amyloid Angiopathy | 2 | 2019 | 101 | 0.220 |
Why?
| | Deep Brain Stimulation | 1 | 2022 | 76 | 0.220 |
Why?
| | Martial Arts | 1 | 2020 | 5 | 0.210 |
Why?
| | Speech Disorders | 1 | 2020 | 15 | 0.210 |
Why?
| | Vision Disorders | 1 | 2020 | 26 | 0.210 |
Why?
| | Hearing Loss, Unilateral | 1 | 2020 | 1 | 0.210 |
Why?
| | Chicago | 2 | 2021 | 955 | 0.210 |
Why?
| | Hyperglycemia | 1 | 2020 | 49 | 0.210 |
Why?
| | Hearing Aids | 1 | 2020 | 3 | 0.210 |
Why?
| | Time and Motion Studies | 1 | 2020 | 13 | 0.210 |
Why?
| | Prevalence | 2 | 2020 | 544 | 0.200 |
Why?
| | Menopause | 1 | 2021 | 121 | 0.200 |
Why?
| | Hypertension | 2 | 2019 | 283 | 0.200 |
Why?
| | Blood Glucose | 1 | 2020 | 137 | 0.200 |
Why?
| | Chemokine CCL5 | 1 | 2019 | 21 | 0.200 |
Why?
| | Societies, Medical | 2 | 2019 | 209 | 0.200 |
Why?
| | Th17 Cells | 1 | 2019 | 33 | 0.200 |
Why?
| | Brain Ischemia | 1 | 2021 | 122 | 0.200 |
Why?
| | Academies and Institutes | 1 | 2018 | 12 | 0.190 |
Why?
| | Research Subjects | 1 | 2018 | 13 | 0.190 |
Why?
| | Sample Size | 1 | 2018 | 26 | 0.190 |
Why?
| | Electroencephalography | 2 | 2013 | 145 | 0.190 |
Why?
| | Health Services Accessibility | 1 | 2020 | 113 | 0.190 |
Why?
| | Dopaminergic Neurons | 1 | 2019 | 50 | 0.180 |
Why?
| | Independent Living | 1 | 2021 | 257 | 0.180 |
Why?
| | Genotype | 3 | 2016 | 423 | 0.180 |
Why?
| | Gene-Environment Interaction | 1 | 2018 | 19 | 0.180 |
Why?
| | Age of Onset | 2 | 2016 | 113 | 0.180 |
Why?
| | Substantia Nigra | 1 | 2019 | 157 | 0.180 |
Why?
| | Estrogens | 1 | 2018 | 36 | 0.180 |
Why?
| | Ibuprofen | 1 | 2017 | 12 | 0.180 |
Why?
| | Animals | 5 | 2022 | 5312 | 0.180 |
Why?
| | Endpoint Determination | 1 | 2017 | 31 | 0.170 |
Why?
| | Patient Acceptance of Health Care | 1 | 2018 | 85 | 0.170 |
Why?
| | Fatigue Syndrome, Chronic | 1 | 2017 | 7 | 0.170 |
Why?
| | Colorado | 2 | 2007 | 5 | 0.170 |
Why?
| | Mosaicism | 1 | 2016 | 9 | 0.170 |
Why?
| | Prospective Studies | 5 | 2021 | 1934 | 0.170 |
Why?
| | Siblings | 1 | 2016 | 19 | 0.160 |
Why?
| | Exercise Test | 1 | 2018 | 123 | 0.160 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 111 | 0.160 |
Why?
| | Comprehension | 1 | 2016 | 31 | 0.160 |
Why?
| | Congresses as Topic | 1 | 2016 | 36 | 0.160 |
Why?
| | Water Wells | 1 | 2016 | 1 | 0.160 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 637 | 0.160 |
Why?
| | Uric Acid | 1 | 2016 | 14 | 0.160 |
Why?
| | Environmental Exposure | 1 | 2016 | 17 | 0.160 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2018 | 230 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2016 | 95 | 0.150 |
Why?
| | Occupational Diseases | 1 | 2016 | 26 | 0.150 |
Why?
| | Computers | 1 | 2015 | 26 | 0.150 |
Why?
| | Child | 3 | 2013 | 1572 | 0.150 |
Why?
| | Early Diagnosis | 1 | 2015 | 76 | 0.150 |
Why?
| | Follow-Up Studies | 4 | 2010 | 2028 | 0.150 |
Why?
| | Reaction Time | 1 | 2015 | 128 | 0.150 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 100 | 0.140 |
Why?
| | Hip Prosthesis | 1 | 2021 | 569 | 0.140 |
Why?
| | Chronic Disease | 1 | 2017 | 544 | 0.140 |
Why?
| | Regression Analysis | 1 | 2015 | 319 | 0.140 |
Why?
| | Range of Motion, Articular | 1 | 2018 | 703 | 0.140 |
Why?
| | Young Adult | 3 | 2013 | 2277 | 0.140 |
Why?
| | Dopamine Agonists | 2 | 2021 | 47 | 0.130 |
Why?
| | Levodopa | 2 | 2021 | 139 | 0.130 |
Why?
| | Hyperkinesis | 1 | 2013 | 12 | 0.130 |
Why?
| | Auditory Pathways | 1 | 2013 | 1 | 0.130 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2013 | 20 | 0.130 |
Why?
| | Audiometry, Pure-Tone | 1 | 2013 | 13 | 0.130 |
Why?
| | England | 1 | 2013 | 22 | 0.130 |
Why?
| | Psychoacoustics | 1 | 2013 | 13 | 0.130 |
Why?
| | Cerebellar Diseases | 1 | 2013 | 11 | 0.130 |
Why?
| | Adolescent | 3 | 2013 | 2667 | 0.130 |
Why?
| | Clinical Protocols | 1 | 2013 | 75 | 0.130 |
Why?
| | Neuronal Plasticity | 1 | 2013 | 50 | 0.130 |
Why?
| | Equipment Design | 1 | 2013 | 198 | 0.120 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2021 | 840 | 0.120 |
Why?
| | Magnetic Resonance Imaging | 3 | 2016 | 1273 | 0.120 |
Why?
| | Double-Blind Method | 1 | 2013 | 559 | 0.120 |
Why?
| | Sex Factors | 2 | 2011 | 542 | 0.110 |
Why?
| | Neurologic Examination | 3 | 2008 | 160 | 0.110 |
Why?
| | Social Behavior Disorders | 1 | 2011 | 5 | 0.110 |
Why?
| | Infant, Newborn | 2 | 2021 | 754 | 0.110 |
Why?
| | Language Disorders | 1 | 2011 | 12 | 0.110 |
Why?
| | Pedigree | 2 | 2008 | 72 | 0.110 |
Why?
| | Cyclohexanols | 1 | 2010 | 18 | 0.110 |
Why?
| | Memantine | 1 | 2010 | 12 | 0.110 |
Why?
| | Point Mutation | 2 | 2008 | 37 | 0.100 |
Why?
| | Cocaine | 1 | 2010 | 45 | 0.100 |
Why?
| | Odds Ratio | 1 | 2011 | 327 | 0.100 |
Why?
| | Corpus Striatum | 1 | 2010 | 116 | 0.100 |
Why?
| | Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 84 | 0.100 |
Why?
| | Atmospheric Pressure | 2 | 2019 | 12 | 0.100 |
Why?
| | Palate, Soft | 1 | 2008 | 1 | 0.090 |
Why?
| | Alexander Disease | 1 | 2008 | 1 | 0.090 |
Why?
| | Heredodegenerative Disorders, Nervous System | 1 | 2008 | 2 | 0.090 |
Why?
| | Exercise Tolerance | 1 | 2007 | 29 | 0.090 |
Why?
| | Glutens | 1 | 2007 | 1 | 0.090 |
Why?
| | Jejunum | 1 | 2007 | 14 | 0.090 |
Why?
| | Chromosome Mapping | 1 | 2007 | 46 | 0.080 |
Why?
| | Research Support as Topic | 1 | 2007 | 20 | 0.080 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2007 | 33 | 0.080 |
Why?
| | Universities | 1 | 2007 | 32 | 0.080 |
Why?
| | North America | 2 | 2018 | 44 | 0.080 |
Why?
| | Education | 1 | 2007 | 42 | 0.080 |
Why?
| | Guidelines as Topic | 1 | 2007 | 79 | 0.080 |
Why?
| | Child, Preschool | 1 | 2009 | 786 | 0.080 |
Why?
| | Peripheral Nervous System Diseases | 1 | 2007 | 38 | 0.080 |
Why?
| | Cholinesterase Inhibitors | 1 | 2006 | 20 | 0.080 |
Why?
| | Carbidopa | 1 | 2006 | 45 | 0.080 |
Why?
| | Benzodiazepines | 1 | 2006 | 59 | 0.080 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2006 | 45 | 0.080 |
Why?
| | Age Factors | 2 | 2021 | 943 | 0.080 |
Why?
| | Biopsy | 1 | 2007 | 283 | 0.080 |
Why?
| | Serotonin Uptake Inhibitors | 1 | 2006 | 90 | 0.080 |
Why?
| | Internet | 1 | 2007 | 103 | 0.080 |
Why?
| | Population Surveillance | 1 | 2006 | 127 | 0.070 |
Why?
| | Anxiety Disorders | 1 | 2006 | 176 | 0.070 |
Why?
| | Pregnancy | 1 | 2006 | 457 | 0.070 |
Why?
| | Registries | 1 | 2006 | 214 | 0.070 |
Why?
| | Intestinal Mucosa | 1 | 2007 | 235 | 0.070 |
Why?
| | DNA Repeat Expansion | 1 | 2004 | 6 | 0.070 |
Why?
| | RNA-Binding Proteins | 1 | 2004 | 26 | 0.070 |
Why?
| | Disease Progression | 3 | 2016 | 861 | 0.060 |
Why?
| | Uterine Diseases | 1 | 2002 | 2 | 0.060 |
Why?
| | Disease Models, Animal | 2 | 2019 | 832 | 0.060 |
Why?
| | Nerve Tissue Proteins | 1 | 2004 | 187 | 0.060 |
Why?
| | Endometriosis | 1 | 2002 | 20 | 0.060 |
Why?
| | Butyrates | 1 | 2022 | 20 | 0.060 |
Why?
| | Task Performance and Analysis | 2 | 2013 | 58 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2004 | 467 | 0.060 |
Why?
| | Dysbiosis | 1 | 2022 | 57 | 0.060 |
Why?
| | Bacteria | 1 | 2022 | 74 | 0.060 |
Why?
| | Animals, Genetically Modified | 1 | 2021 | 18 | 0.060 |
Why?
| | Fertility | 1 | 2021 | 19 | 0.060 |
Why?
| | Drosophila melanogaster | 1 | 2021 | 21 | 0.060 |
Why?
| | Physical Therapy Modalities | 2 | 2012 | 70 | 0.060 |
Why?
| | Proteome | 1 | 2021 | 31 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2021 | 82 | 0.050 |
Why?
| | Surface Properties | 1 | 2021 | 139 | 0.050 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2021 | 177 | 0.050 |
Why?
| | Corrosion | 1 | 2021 | 127 | 0.050 |
Why?
| | Materials Testing | 1 | 2021 | 140 | 0.050 |
Why?
| | Life Style | 1 | 2022 | 219 | 0.050 |
Why?
| | Noise | 1 | 2020 | 32 | 0.050 |
Why?
| | Cochlear Implants | 1 | 2020 | 25 | 0.050 |
Why?
| | Genome-Wide Association Study | 1 | 2021 | 315 | 0.050 |
Why?
| | Databases, Factual | 1 | 2022 | 391 | 0.050 |
Why?
| | Feasibility Studies | 1 | 2020 | 281 | 0.050 |
Why?
| | Nerve Degeneration | 1 | 2019 | 57 | 0.050 |
Why?
| | Temperature | 1 | 2018 | 85 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2004 | 891 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 389 | 0.050 |
Why?
| | Prosthesis Design | 1 | 2021 | 511 | 0.040 |
Why?
| | Risk Assessment | 1 | 2021 | 806 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2019 | 548 | 0.040 |
Why?
| | Hospitalization | 1 | 2020 | 359 | 0.040 |
Why?
| | Comorbidity | 1 | 2019 | 562 | 0.040 |
Why?
| | Prognosis | 1 | 2020 | 1028 | 0.040 |
Why?
| | Self Report | 1 | 2018 | 225 | 0.040 |
Why?
| | Prosthesis Failure | 1 | 2021 | 534 | 0.040 |
Why?
| | Accelerometry | 1 | 2017 | 88 | 0.040 |
Why?
| | Logistic Models | 1 | 2018 | 479 | 0.040 |
Why?
| | Protective Factors | 1 | 2016 | 19 | 0.040 |
Why?
| | Posture | 1 | 2016 | 92 | 0.040 |
Why?
| | Occupational Exposure | 1 | 2016 | 27 | 0.040 |
Why?
| | Neuroimaging | 1 | 2016 | 126 | 0.040 |
Why?
| | Mice | 1 | 2019 | 1894 | 0.030 |
Why?
| | Video Recording | 1 | 2014 | 52 | 0.030 |
Why?
| | Single-Blind Method | 1 | 2013 | 132 | 0.030 |
Why?
| | Movement | 1 | 2013 | 167 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2013 | 362 | 0.030 |
Why?
| | Mental Health | 1 | 2013 | 119 | 0.030 |
Why?
| | Health Status | 1 | 2013 | 249 | 0.030 |
Why?
| | Statistics, Nonparametric | 1 | 2011 | 156 | 0.030 |
Why?
| | Chi-Square Distribution | 1 | 2011 | 178 | 0.030 |
Why?
| | Linear Models | 1 | 2011 | 276 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2010 | 265 | 0.030 |
Why?
| | Pons | 1 | 2008 | 4 | 0.020 |
Why?
| | Mental Processes | 1 | 2008 | 18 | 0.020 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2008 | 36 | 0.020 |
Why?
| | Intelligence | 1 | 2008 | 28 | 0.020 |
Why?
| | Family Health | 1 | 2007 | 38 | 0.020 |
Why?
| | Verbal Learning | 1 | 2008 | 43 | 0.020 |
Why?
| | Atrophy | 1 | 2008 | 108 | 0.020 |
Why?
| | Memory, Short-Term | 1 | 2008 | 99 | 0.020 |
Why?
| | Gene Silencing | 1 | 2007 | 26 | 0.020 |
Why?
| | Patient Compliance | 1 | 2007 | 200 | 0.020 |
Why?
| | Mass Screening | 1 | 2007 | 199 | 0.020 |
Why?
| | California | 1 | 2004 | 35 | 0.020 |
Why?
| | Endometrium | 1 | 2002 | 7 | 0.020 |
Why?
| | Leiomyoma | 1 | 2002 | 11 | 0.020 |
Why?
| | Uterine Neoplasms | 1 | 2002 | 13 | 0.020 |
Why?
| | Ultrasonography | 1 | 2002 | 210 | 0.010 |
Why?
|
|
Hall's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|